Abstract:Objectives The Rho guanosine triphosphatases (Rho GTPases)family, including RhoA, plays an important part in angiotensin II (Ang II)-mediated cardiac fibrosis. Farnesyl pyrophosphate synthase (FPPS)-catalysed isoprenoid intermediates are important for activation of RhoA. Evidence is accumulated for crucial role of FPPS in the process of cardiac hypertrophy and fibrosis. The present study was designed to investigate the role of FPPS in cardiac fibrosis induced by Ang II. Methods In vivo and in vitro model of cardiac fibrosis were settled by Ang II. FPPS expression was measured by Western blot and qRT-PCR. Cultured neonatal cardiac fibroblasts (NCFs) proliferation was determined by Cell Counting Kit-8 assay and Edu assay. The role of FPPS was both estimated by FPPS inhibitor (zolendronate) and RNA interference (RNAi) against FPPS in NCFs. RhoA activation was evaluated by pull-down assay. Results First, We demonstrated that FPPS expression was elevated both in the in vitro model of NCFs and in the in vivo model of myocardium by Ang II. Then, FPPS inhibition by zolendronate decreased cardiac fibrosis marker gene of collagen I, collagen III and transforming growth factor β1(TGFβ1). Furthermore, the inhibition was reversed with geranylgerananyol (GGOH) and mimicked by Rho inhibitor, suggesting that the anti-fibrotic effect of zolendronate might be via limitation of RhoA geranylgeranylation. Pull-down assay showed that zolendronate reduced active RhoA by Ang II, which was also partially antagonised by GGOH. In addition, FPPS specifically knocking-down prevented expression of collagen I, collagen II and TGF β1, as well as prevented elevated RhoA activity by Ang II compared with non-silencing controls. Conclusions This study reveals FPPS elevation in Ang II-induced cardiac fibrosis model both in vivo and in vitro model. The inhibition and knockdown of FPPS reduces RhoA activation by diminishing geranylgeranylation which prevents Ang II-induced collagen I, collagen III, TGF β1 expression.

Knockdown of farnesylpyrophosphate synthase prevents angiotensin II-mediated cardiac hypertrophy.

Inhibition of farnesyl pyrophosphate synthase attenuates angiotensin II-induced cardiac hypertrophy and fibrosis in vivo.

Cardiac-specific Overexpression of Farnesyl Pyrophosphate Synthase Induces Cardiac Hypertrophy and Dysfunction in Mice.

Chronic inhibition of farnesyl pyrophosphate synthase attenuates cardiac hypertrophy and fibrosis in spontaneously hypertensive rats.

Inhibition of Farnesyl Pyrophosphate Synthase Improves Pressure Overload Induced Chronic Cardiac Remodeling

Expression of Farnesyl Pyrophosphate Synthase is Increased in Diabetic Cardiomyopathy.

Inhibition of Farnesylpyrophosphate Synthase Prevents Angiotensin II-induced Hypertrophic Responses in Rat Neonatal Cardiomyocytes: Involvement of the RhoA/Rho Kinase Pathway

GW24-e2384 the Role of Farnesyl Pyrophosphate Synthase in Angiotensin II-induced Cardiac Fibrosis

Knock-down of Farnesyl Pyrophosphate Synthase Protects Heart-Derived H9c2 Cells Against Hypoxia/reoxygenation-Induced Injury.

Inhibition of Farnesyl Pyrophosphate Synthase Prevents Angiotensin II-induced Cardiac Fibrosis in Vitro.

Chronic inhibition of farnesyl pyrophosphate synthase improves endothelial function in spontaneously hypertensive rats.

Inhibition of Farnesyl Pyrophosphate Synthase Prevents Norepinephrine–induced Fibrotic Responses in Vascular Smooth Muscle Cells from Spontaneously Hypertensive Rats

Alteration of RhoA Prenylation Ameliorates Cardiac and Vascular Remodeling in Spontaneously Hypertensive Rats.

Effect of farnesyltransferase inhibition on cardiac remodeling in spontaneously hypertensive rats

GW24-e2448 Knockdown of Farnesyl Pyrophosphate Synthase Prevents Cardiac Fibrosis of Spontaneously Hypertensive Ratsin Vivo

Establishment of transgenic mice carrying the gene for farnesyl pyrophosphate synthase

Knock-down of Farnesyl Pyrophosphate Synthase Protects Heart-derived H 9 c 2 Cells Against Hypoxia / Reoxygenation-Induced Injury † Running title Effect of FPPS on HR Injury in H 9 c 2 Cells

Cardiac‐specific Deletion of FDPS Induces Cardiac Remodeling and Dysfunction by Enhancing the Activity of Small GTP‐binding Proteins

Overexpression of Farnesyl Pyrophosphate Synthase Increases Myocardial Ischemia/reperfusion Injury in Mice.

Mitogen-activated protein kinases ERK 1/2-and p38-GATA-4 pathways mediate the Ang II-induced activation of FGF-2 gene in neonatal rat cardiomyocytes

PFKP inhibition protects against pathological cardiac hypertrophy by regulating protein synthesis